Trajectories and risk factors for anxiety and depression in children and adolescents with cancer: A 1-year follow-up.
PROMIS
anxiety
cancer
depression
longitudinal
risk-factors
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
19
04
2021
accepted:
04
06
2021
pubmed:
27
7
2021
medline:
19
2
2022
entrez:
26
7
2021
Statut:
ppublish
Résumé
There is limited data on the longitudinal trajectories of psychiatric disorders in children with cancer and risk factors for their persistence. The current study aimed to longitudinally assess the trajectories and risk factors for anxiety and depressive symptoms and disorders in children and adolescents with cancer. Children and adolescents with cancer and their parents completed the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression and Anxiety Module and were interviewed by the semi-structured Affective and Anxiety Modules of the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS), at 4 time points, 1, 4, 7, and 12 months following the diagnosis of cancer. Of the 99 patients enrolled, 48% met criteria for anxiety and/or depressive disorders at least once during the follow-up period. There was a significant decrease in PROMIS pediatric and parent anxiety and depression scores (all p's < 0.01) and in the rate of depressive disorders over time (p = 0.02), while rates of anxiety disorders remained stable. Anxiety PROMIS pediatric and parent scores at baseline, having brain tumors and being in the acute treatment phase significantly predicted the presences of anxiety disorders at endpoint. Our results highlight the importance of screening for anxiety and disorders in children with cancer, especially among those with brain tumors and at the acute phase of treatment.
Sections du résumé
BACKGROUND
There is limited data on the longitudinal trajectories of psychiatric disorders in children with cancer and risk factors for their persistence. The current study aimed to longitudinally assess the trajectories and risk factors for anxiety and depressive symptoms and disorders in children and adolescents with cancer.
METHODS
Children and adolescents with cancer and their parents completed the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression and Anxiety Module and were interviewed by the semi-structured Affective and Anxiety Modules of the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS), at 4 time points, 1, 4, 7, and 12 months following the diagnosis of cancer.
RESULTS
Of the 99 patients enrolled, 48% met criteria for anxiety and/or depressive disorders at least once during the follow-up period. There was a significant decrease in PROMIS pediatric and parent anxiety and depression scores (all p's < 0.01) and in the rate of depressive disorders over time (p = 0.02), while rates of anxiety disorders remained stable. Anxiety PROMIS pediatric and parent scores at baseline, having brain tumors and being in the acute treatment phase significantly predicted the presences of anxiety disorders at endpoint.
CONCLUSIONS
Our results highlight the importance of screening for anxiety and disorders in children with cancer, especially among those with brain tumors and at the acute phase of treatment.
Identifiants
pubmed: 34309238
doi: 10.1002/cam4.4100
pmc: PMC8366094
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5653-5660Subventions
Organisme : Foundation Dora
Organisme : Gesner Foundation for Medical Research
Organisme : Israel Cancer Association
ID : 20170158
Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8
pubmed: 9204677
Int J Environ Res Public Health. 2020 Jan 16;17(2):
pubmed: 31963108
J Natl Cancer Inst Monogr. 2004;(32):57-71
pubmed: 15263042
Pediatr Blood Cancer. 2017 Apr;64(4):
pubmed: 27808460
Cancer. 2016 May 15;122(10):1608-17
pubmed: 27028090
Pediatrics. 1987 May;79(5):805-13
pubmed: 2952939
Support Care Cancer. 2011 Sep;19(9):1275-87
pubmed: 21611865
J Pediatr Hematol Oncol. 2005 Jan;27(1):15-22
pubmed: 15654273
J Pediatr Endocrinol Metab. 2002 May;15 Suppl 2:669-73
pubmed: 12092679
Turk J Med Sci. ;47(4):1078-1088
pubmed: 29153555
JAMA Pediatr. 2020 Nov 1;174(11):e202861
pubmed: 32832975
Cancer. 2014 May 1;120(9):1417-25
pubmed: 24473774
J Pediatr Nurs. 2001 Oct;16(5):380-5
pubmed: 11598872
Acta Paediatr. 2000 Feb;89(2):229-36
pubmed: 10709896
Acta Diabetol. 2015 Apr;52(2):365-71
pubmed: 25267080
J Pain Symptom Manage. 2013 Sep;46(3):366-75
pubmed: 23498966
Cancer Med. 2021 Aug;10(16):5653-5660
pubmed: 34309238
Pediatr Blood Cancer. 2008 Feb;50(2):289-92
pubmed: 17514742
J Am Acad Child Adolesc Psychiatry. 1997 Dec;36(12):1736-43
pubmed: 9401335
Psychooncology. 2019 Apr;28(4):710-717
pubmed: 30669186
Pediatr Blood Cancer. 2012 Oct;59(4):717-24
pubmed: 22294502
Psychooncology. 2020 Nov;29(11):1959-1967
pubmed: 33068463
Psychooncology. 2020 Dec;29(12):2019-2027
pubmed: 32691478
Health Qual Life Outcomes. 2006 Sep 20;4:63
pubmed: 16987419
J Pediatr Hematol Oncol. 2000 May-Jun;22(3):214-20
pubmed: 10864052